secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0000950170-21-003055
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q3 cash $803.6M; FT596/FT516 show 71% and 73% ORR in lymphoma Ph1
--------------------------------------------------------------------------------

- Cash, equivalents and investments $803.6M at Sept 30, 2021; revenue $14.2M from collaborations.
- FT596 in r/r BCL: 71% ORR, 50% CR in single-dose cohorts; no ICANS or GVHD, two low-grade CRS events.
- FT516 in r/r BCL: 73% ORR, 55% CR in multi-dose cohorts; 63% responders ongoing at median 5.2 months.
- FT819 (iPSC-derived CAR T) first patients dosed; FT576 Ph1 enrollment initiated for multiple myeloma.
- R&D expenses $53.1M, G&A $15.7M; shares outstanding 95.4M common, 2.8M preferred (convertible 5:1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017021003055/0000950170-21-003055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017021003055/fate-20211104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer